INR 6082.6
(-0.65%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 8.86 Billion INR | 3.58% |
2022 | 9.07 Billion INR | -6.55% |
2021 | 13.26 Billion INR | 3.05% |
2020 | 7.61 Billion INR | 5.83% |
2019 | 6.99 Billion INR | 6.48% |
2018 | 7.12 Billion INR | 15.47% |
2017 | 6.16 Billion INR | 3.42% |
2016 | 5.99 Billion INR | 17.11% |
2015 | 5.1 Billion INR | 27.21% |
2014 | 3.55 Billion INR | -10.64% |
2013 | 4.15 Billion INR | 27.4% |
2012 | 3.51 Billion INR | 11.58% |
2011 | 3.15 Billion INR | 23.28% |
2010 | 2.53 Billion INR | -0.96% |
2009 | 2.58 Billion INR | -7.05% |
2008 | 2.78 Billion INR | 15.44% |
2007 | 2.36 Billion INR | -10.04% |
2006 | 2.63 Billion INR | 5.73% |
2005 | 2.5 Billion INR | 7.43% |
2004 | 2.36 Billion INR | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q1 | 2.18 Billion INR | -0.35% |
2024 Q2 | 1.15 Billion INR | -48.92% |
2023 Q1 | 2.55 Billion INR | 36.81% |
2023 FY | - INR | 3.58% |
2023 Q2 | 1.93 Billion INR | -24.17% |
2023 Q4 | 1.87 Billion INR | -14.82% |
2023 Q3 | 2.2 Billion INR | 13.46% |
2022 FY | - INR | -6.55% |
2022 Q2 | 1.76 Billion INR | -19.23% |
2022 Q3 | 1.93 Billion INR | 9.33% |
2022 Q4 | 1.86 Billion INR | -3.31% |
2022 Q1 | 2.18 Billion INR | 59.9% |
2021 Q1 | 2.15 Billion INR | 15.97% |
2021 Q3 | 2.13 Billion INR | -19.19% |
2021 Q4 | 1.36 Billion INR | -35.88% |
2021 Q2 | 2.64 Billion INR | 22.48% |
2021 FY | - INR | 3.05% |
2020 FY | - INR | 5.83% |
2020 Q4 | 1.86 Billion INR | -10.19% |
2020 Q3 | 2.07 Billion INR | 0.34% |
2020 Q2 | 2.06 Billion INR | 0.1% |
2020 Q1 | 2.06 Billion INR | 0.63% |
2019 Q4 | 2.04 Billion INR | 3.28% |
2019 Q1 | 3.28 Billion INR | 108.89% |
2019 Q2 | 1.81 Billion INR | -44.89% |
2019 Q3 | 1.98 Billion INR | 9.49% |
2019 FY | - INR | 6.48% |
2018 Q2 | 1.85 Billion INR | 18.03% |
2018 Q4 | 1.57 Billion INR | -26.28% |
2018 FY | - INR | 15.47% |
2018 Q1 | 1.57 Billion INR | 2.88% |
2018 Q3 | 2.13 Billion INR | 15.22% |
2017 Q3 | 2.04 Billion INR | 42.21% |
2017 Q2 | 1.43 Billion INR | 22.49% |
2017 Q1 | 1.17 Billion INR | -4.16% |
2017 FY | - INR | 3.42% |
2017 Q4 | 1.52 Billion INR | -25.38% |
2016 Q4 | 1.22 Billion INR | -23.2% |
2016 FY | - INR | 17.11% |
2016 Q3 | 1.59 Billion INR | -1.66% |
2016 Q2 | 1.62 Billion INR | 4.85% |
2016 Q1 | 1.54 Billion INR | 23.27% |
2015 Q3 | 1.51 Billion INR | 15.23% |
2015 FY | - INR | 27.21% |
2015 Q4 | 1.25 Billion INR | -17.05% |
2015 Q1 | 1.02 Billion INR | 43.52% |
2015 Q2 | 1.31 Billion INR | 28.35% |
2014 Q2 | 1.11 Billion INR | 8.68% |
2014 Q3 | 1.18 Billion INR | 5.92% |
2014 FY | - INR | -10.64% |
2014 Q4 | 712.8 Million INR | -39.59% |
2014 Q1 | 1.02 Billion INR | -18.37% |
2013 Q4 | 1.25 Billion INR | -10.25% |
2013 Q2 | 1.01 Billion INR | 15.53% |
2013 Q1 | 882 Million INR | -0.77% |
2013 FY | - INR | 27.4% |
2013 Q3 | 1.39 Billion INR | 37.29% |
2012 Q3 | 1.07 Billion INR | 35.74% |
2012 Q4 | 888.8 Million INR | -17.01% |
2012 Q2 | 789 Million INR | 1.02% |
2012 Q1 | 781 Million INR | 13.06% |
2012 FY | - INR | 11.58% |
2011 Q2 | 789 Million INR | 0.0% |
2011 Q4 | 690.8 Million INR | -20.78% |
2011 Q3 | 872 Million INR | 10.52% |
2011 FY | - INR | 23.28% |
2010 FY | - INR | -0.96% |
2009 FY | - INR | -7.05% |
2008 FY | - INR | 15.44% |
2007 FY | - INR | -10.04% |
2006 FY | - INR | 5.73% |
2005 FY | - INR | 7.43% |
2004 FY | - INR | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Abbott India Limited | 16.97 Billion INR | 47.768% |
Cipla Limited | 67.19 Billion INR | 86.803% |
Gland Pharma Limited | 13.33 Billion INR | 33.477% |
GlaxoSmithKline Pharmaceuticals Limited | 8.87 Billion INR | 0.056% |
Kopran Limited | 744.13 Million INR | -1091.718% |
Marksans Pharma Limited | 4.58 Billion INR | -93.381% |
NGL Fine-Chem Limited | 678.68 Million INR | -1206.643% |
Pfizer Limited | 8.23 Billion INR | -7.65% |
SMS Pharmaceuticals Limited | 1.21 Billion INR | -632.413% |
TTK Healthcare Limited | 999.34 Million INR | -787.381% |